Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

bluebird bio, Inc. - Common Stock (NQ:BLUE)

4.970 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about bluebird bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital
From bluebird bio
Via Business Wire
Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer
From bluebird bio, Inc.
Via Business Wire
bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital
From bluebird bio, Inc.
Via Business Wire
Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions
From bluebird bio, Inc.
Via Business Wire
Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement
From bluebird bio, Inc.
Via Business Wire
Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital
From bluebird bio, Inc.
Via Business Wire
Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio
From bluebird bio, Inc.
Via Business Wire
bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement
From bluebird bio, Inc.
Via Business Wire
bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid
From bluebird bio, Inc.
Via Business Wire
BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE
From Kahn Swick & Foti, LLC
Via Business Wire
BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE
From Kahn Swick & Foti, LLC
Via Business Wire
Shareholder Alert: Ademi LLP investigates whether bluebird bio, Inc. is obtaining a Fair Price for its Public Shareholders
From Ademi LLP
Via Business Wire
BLUE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of bluebird bio, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital
From bluebird bio, Inc.
Via Business Wire
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
From bluebird bio, Inc.
Via Business Wire
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
From bluebird bio, Inc.
Via Business Wire
bluebird bio Announces 1-for-20 Reverse Stock Split
From bluebird bio, Inc.
Via Business Wire
bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model
From bluebird bio, Inc.
Via Business Wire
bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
From bluebird bio, Inc.
Via Business Wire
bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call
From bluebird bio, Inc.
Via Business Wire
bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
From bluebird bio, Inc.
Via Business Wire
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From bluebird bio, Inc.
Via Business Wire
bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing
From bluebird bio, Inc.
Via Business Wire
bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025
From bluebird bio, Inc.
Via Business Wire
bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q
From bluebird bio, Inc.
Via Business Wire
bluebird bio Announces September Investor Events
From bluebird bio, Inc.
Via Business Wire
bluebird bio Announces Receipt of Expected Notices from Nasdaq
From bluebird bio, Inc.
Via Business Wire
bluebird bio Reports Second Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
From bluebird bio, Inc.
Via Business Wire
bluebird bio Announces Second Quarter 2024 Results Call Date
From bluebird bio, Inc.
Via Business Wire
CS Diagnostics (OTC: FZRO) Acquisitions Announced, Landmark Agreement Signed, Moving Forward Through 2024
Via AB Newswire
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback